Topical Sulfasalazine & Oral Lichen Planus

Status Active, not recruiting

Clinical Trial Summary

Oral lichen planus (OLP) is a chronic inﬂammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown. Sulfasalazine is extensively used in inﬂammatory bowel disease and is effective on immune-related inﬂammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inﬂammatory mechanism is not clearly understood.

Clinical Trial Description

- Patients will be recruited in a consecutive manner from the outpatient Diagnostic center, Faculty of Dentistry, Cairo University. - A total number of 46 patients will be included in this study. The 23 patients categorized as study group (S group) will use topical sulfasalazine prepared by dissolving one tablet of commercially available (COLOSALAZINE - EC 500 MG 20 TAB, manufactured by: Alexandria Company for Pharmaceuticals & Chemical Industries, Alexandria) in 100 ml of distilled water 4 times per day as a mouth wash combined with topical corticosteroids 4 times per day as a topical gel in an alternate sequence. There are no expected side effects of this treatment due to its topical application however, the patient will be instructed to stop the treatment if any adverse reactions occur such as allergy and coming to the clinic next day. - The 23 patients categorized as control group (C group) will receive topical corticosteroids gel only 4 times per day. The treatment regimen will be continued for 4 weeks with follow up visits one per week. - Medical history will be taken, thorough oral examination will be done, and a full questionnaire will be filled for each patient. - All participants in the study groups will undergo adequate oral hygiene performance measures with complete removal of plaque and calculus as they implement intraoral inflammation and intensify both extension and symptoms of OLP lesions. Patients will be advised to evade accidental trauma on soft tissues using soft bristles toothbrush. Acidic, spicy, hard, hot food and beverages will be avoided. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06060301
Study type	Interventional
Source	Cairo University
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	March 1, 2023
Completion date	November 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05997173` - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed	`NCT02443311` - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus	Phase 4
Completed	`NCT00484250` - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other	Phase 2
Completed	`NCT03682562` - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Not yet recruiting	`NCT06428630` - Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus	Early Phase 1
Completed	`NCT04193748` - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)	Phase 4
Completed	`NCT04153266` - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting	`NCT06135805` - Impact of Fluocinonide 0,05% in Oral Lichen Planus	N/A
Completed	`NCT04289233` - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed	`NCT04293718` - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed	`NCT00525421` - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus	Phase 2
Not yet recruiting	`NCT04091698` - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial	Phase 1
Completed	`NCT03386643` - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus	Phase 2
Withdrawn	`NCT03836885` - Apremilast - Oral Lichen Planus Trial	Phase 2
Completed	`NCT05730855` - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed	`NCT03257228` - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)	N/A
Recruiting	`NCT03026478` - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus	Phase 2
Completed	`NCT02858297` - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus	Phase 4
Completed	`NCT02834520` - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus	N/A
Completed	`NCT02106468` - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Topical Sulfasalazine and Oral Lichen Planus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms